Pharma Firms Need To Pressure Politicians On Brexit Priorities

03 Aug 2018

Pharmaceutical companies need to get their message over to MPs and MEPs about the risks of Brexit to medicines supply chains, and would do well to work more closely with patient groups to highlight the possible health risks of reduced access to medicines.

PS1806_Clouds Obscuring Sun_1055974544_1200.jpg — Brexit storm clouds continue to gather over the pharma sector

With the prospect of a “no-deal” outcome to the Brexit negotiations looking increasingly likely, pharmaceutical companies have been told that they need to do more to convince UK and EU policy makers of the need for market certainty and continued timely access to medicines after the UK leaves the EU.

According to a survey of UK members of parliament (MPs) and members of the European Parliament (MEPs) conducted by...